BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

November 30, 2003

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions

Leukemia, Myeloid, Chronic-phaseLeukemia, Lymphoblastic, Acute, Philadelphia-positive

Interventions

DRUG

Dasatinib

Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.

Trial Locations (2)

Local Institution, Los Angeles

Local Institution, Houston